Friday, February 24, 2017 5:04:45 AM
Knowing second-line anti-PD-1 non-responder treatments for advanced melanoma are reserved primarily for Yervoy (around 10% ORR in anti-PD-1 non-responder population), you can either go the route of combining Keytruda with Yervoy and get on the order of 50% grade 3-4 AEs, 35% dropouts, and 20% best overall responses, or you put a patient on an ImmunoPulse IL-12/keytruda combination that observes less than 5% grade 3-4 AEs, 0% dropouts, and thus far achieves 30% responses (including complete response).
Merck needs a therapy in the anti-PD-1 non-responder setting for advanced melanoma - they don't have an anti-ctla-4 checkpoint inhibitor like BMY's Yervoy. This is clearly an untapped market for Merck.
Don't ask me why the market reacted the way it did to the data announcement - these aren't treatment naive first-line patients. Existing therapies in the anti-PD-1 non-responder second line setting for advanced melanoma are clearly more toxic and less effective.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM